Pharmacyclics, Inc. (PCYC)

[crudeoil24]

It ain't over until it's over > "PCYC has traded higher the last couple weeks behind rumors that JNJ is nearing a deal to acquire the company.
Instead, AbbVie announced it was buying PCYC for $21 billion, at least $3 billion higher than JNJ's bid.
While this may seem like a closed book, PCYC investors should hold out a little bit longer, as counter bids might very well follow.
AbbVie (NYSE:ABBV) has beaten Johnson & Johnson (NYSE:JNJ) to the punch, outbidding to acquire Pharmacyclics (NASDAQ:PCYC) for $21 billion. Given the speculation that surrounded the acquisition of Pharmacyclics, this outcome is a big shock, as investors almost universally thought Johnson & Johnson was nearing a deal. Therefore, with AbbVie stating that it is the one to acquire Pharmacyclics, it appears like a done deal, that Pharmacyclics and its drug Imbruvica will belong to AbbVie. However, I wouldn't close this book just yet."